• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sonder Capital Appoints Kate Garrett as Managing Partner to Lead Next Generation of Growth

    4/2/24 8:00:00 AM ET
    $ISRG
    $PRCT
    $SWAV
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ISRG alert in real time by email

    Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II

    Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund.

    With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created positions of Co-chairs to help guide and support future growth. This strategic move comes as Sonder continues to accelerate innovation, foster innovative leadership, and invest in the next generation of transformative healthcare technologies.

    A respected and well-known leader in the healthcare innovation community, Garrett serves on the board of Sonder portfolio companies Spirair, BRIUS Technologies, Ziteo, and Neptune Medical. She brings nearly two decades of experience as a successful inventor, founder, and operator across a wide spectrum of companies from early-stage startups to multinational organizations. Among her many achievements, Garrett co-founded and led Ciel Medical in the invention, development and commercialization of critical care products for ventilated patients. The company was acquired by Vyaire Medical in 2017. She also serves as Assistant Director of the Stanford Biodesign Innovation Fellowship, where she guides emerging inventors and entrepreneurs in the discovery and development of breakthrough technologies that solve significant unmet healthcare needs.

    "I am honored to have the opportunity to lead our partnership into our next phase of development," said Garrett. "With unsustainable costs and an aging patient population, the fundamental need for better healthcare solutions is as great as ever. These are the types of challenges Sonder is working to address."

    "Kate is the ideal leader for our next generation of growth and innovation," said Watkins. "She is an extraordinary, empathetic team builder who is respected by investors and entrepreneurs alike. Her passion for scaling technologies and developing leaders is critical to our portfolio and firm's success," he said.

    "As we close our second fund, it's crucial for us to have a leader who can collaborate with our partners to build a dynamic infrastructure that will further support and accelerate our growth," said Moll. "Kate has a unique blend of capabilities with her success as an inventor, founder, and operator, and her prominence as a leader and mentor in the healthcare innovation community. Her skills and vision will play a key role in taking us through our next phase of growth," he said.

    About Sonder Capital

    Sonder's team of veteran investors, innovators, founder-operators, and company builders is known not only for their individual achievements, but also for their collective success in creating, funding, and leading private and public companies that have transformed healthcare for millions of patients globally — including Intuitive Surgical (NASDAQ:ISRG), Shockwave Medical (NASDAQ:SWAV), Procept Biorobotics (NASDAQ:PRCT), Auris Health, and Reflexion Medical, among others. Sonder's extensive network of limited partners is global and includes industry leaders, high-net-worth individuals, and leading family offices focused on investing in game-changing healthcare technologies. Sonder Capital was co-founded in 2019 by healthcare luminaries Jay Watkins and Fred Moll, M.D.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240401500277/en/

    Get the next $ISRG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISRG
    $PRCT
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Intuitive Surgical Inc.
    $ISRG
    7/9/2026$518.00Outperform
    BMO Capital Markets
    PROCEPT BioRobotics Corporation
    $PRCT
    7/6/2026$25.00Buy → Hold
    Truist
    PROCEPT BioRobotics Corporation
    $PRCT
    6/24/2026$30.00Outperform
    Evercore ISI
    PROCEPT BioRobotics Corporation
    $PRCT
    6/11/2026$29.00Outperform → Market Perform
    Leerink Partners
    Intuitive Surgical Inc.
    $ISRG
    3/11/2026$590.00Neutral → Buy
    Citigroup
    PROCEPT BioRobotics Corporation
    $PRCT
    3/6/2026$30.00Neutral
    Robert W. Baird
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026Outperform → Perform
    Oppenheimer
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026$20.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $ISRG
    $PRCT
    $SWAV
    SEC Filings

    View All

    SEC Form S-8 filed by Intuitive Surgical Inc.

    S-8 - INTUITIVE SURGICAL INC (0001035267) (Filer)

    7/21/26 5:28:51 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Intuitive Surgical Inc.

    10-Q - INTUITIVE SURGICAL INC (0001035267) (Filer)

    7/21/26 5:25:51 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    Intuitive Surgical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)

    7/16/26 4:05:17 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intuitive Announces Second Quarter Earnings

    SUNNYVALE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2026. Q2 Highlights Worldwide procedures (da Vinci and Ion combined) grew approximately 16% compared with the second quarter of 2025. Da Vinci procedures grew approximately 15%, and Ion procedures grew approximately 36%.The Company placed 468 da Vinci surgical systems, compared with 395 in the second quarter of 2025. The second quarter 2026 da Vinci surgical system placements included 246 da Vinci 5 systems, compared with 180 in the s

    7/16/26 4:05:00 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    Mobia Medical Appoints Reza Zadno, Ph.D., to its Board of Directors

    AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (NASDAQ:MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee. "We are pleased to welcome Reza to the Mobia Medical Board of Directors," said Richard Foust, President and Chief Executive Officer of Mobia Medical. "He has built and scaled multiple public medical technology companies, and his operational perspective and public company governance experience wi

    7/15/26 4:05:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026

    SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/8fznodv2 Dial-in registration for sell-side research ana

    7/14/26 4:05:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Desai Antal Rohit bought $10,482,943 worth of shares (426,262 units at $24.59) (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/9/26 7:19:42 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer (CEO) Rosa David J. converted options into 1,910 shares and covered exercise/tax liability with 947 shares, increasing direct ownership by 0.39% to 246,856 units (SEC Form 4) (tax withholding)

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    7/13/26 5:54:46 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    EVP & Chief Mfg and Supply Cha Brosius Mark sold $19,833 worth of shares (48 units at $413.19) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,406 units (SEC Form 4)

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    6/12/26 6:29:21 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    EVP & Chief Mfg and Supply Cha Brosius Mark sold $29,104 worth of shares (69 units at $421.80) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 1,454 units (SEC Form 4)

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    6/10/26 6:01:06 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BMO Capital Markets initiated coverage on Intuitive Surgical with a new price target

    BMO Capital Markets initiated coverage of Intuitive Surgical with a rating of Outperform and set a new price target of $518.00

    7/9/26 9:29:25 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    PROCEPT BioRobotics downgraded by Truist with a new price target

    Truist downgraded PROCEPT BioRobotics from Buy to Hold and set a new price target of $25.00

    7/6/26 8:45:49 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on PROCEPT BioRobotics with a new price target

    Evercore ISI initiated coverage of PROCEPT BioRobotics with a rating of Outperform and set a new price target of $30.00

    6/24/26 8:43:50 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    Mobia Medical Appoints Reza Zadno, Ph.D., to its Board of Directors

    AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (NASDAQ:MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee. "We are pleased to welcome Reza to the Mobia Medical Board of Directors," said Richard Foust, President and Chief Executive Officer of Mobia Medical. "He has built and scaled multiple public medical technology companies, and his operational perspective and public company governance experience wi

    7/15/26 4:05:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Intel Appoints Dr. Craig H. Barratt to Board of Directors

    Intel Corporation (NASDAQ:INTC) today announced that Craig H. Barratt, Ph.D., 63, has been appointed to its board of directors, effective immediately. Dr. Barratt will serve as an independent director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110908011/en/Dr. Craig H. Barratt joins Intel's board as an independent director. "Craig is a highly accomplished technology leader with a proven ability to innovate, scale, and transform businesses," said Lip-Bu Tan, Intel CEO. "He is a seasoned semiconductor executive with experience at multiple leading-edge technology companies, which will be invaluable as we continue to execute

    11/10/25 6:21:00 PM ET
    $ALAB
    $INTC
    $ISRG
    Semiconductors
    Technology
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/14/24 1:28:32 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/12/24 5:01:10 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/4/24 1:31:19 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Financials

    Live finance-specific insights

    View All

    Intuitive Announces Second Quarter Earnings

    SUNNYVALE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2026. Q2 Highlights Worldwide procedures (da Vinci and Ion combined) grew approximately 16% compared with the second quarter of 2025. Da Vinci procedures grew approximately 15%, and Ion procedures grew approximately 36%.The Company placed 468 da Vinci surgical systems, compared with 395 in the second quarter of 2025. The second quarter 2026 da Vinci surgical system placements included 246 da Vinci 5 systems, compared with 180 in the s

    7/16/26 4:05:00 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026

    SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/8fznodv2 Dial-in registration for sell-side research ana

    7/14/26 4:05:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

    SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2026. "Over the past six months, we have taken decisive actions to reset the organization by sharpening our focus on operational excellence, accountability, and commercial discipline, and our first quarter results reflect the early impact of that work," said Larry Wood, Chief Executive Officer. "We delivered $83.1 million in revenue, driven by strong U.S. system sales and improved pricing.

    4/29/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care